Successful pilot roll-out of Alzheimer’s Disease Prediction Service (ADPS) in 5 European Countries and the USA

Next Phase includes roll-out in Africa

The Alzheimer’s Disease Prediction Service (ADPS) project is an Innovation by Ideas project supported by EIT Health. It is bound to be one of the first validated solutions to enter the EU market as a pre-symptomatic, computational biomarker to predict Alzheimer’s risk for people over 50. First results from a hugely successful pilot roll-out in the USA, Spain, Greece, Italy, Ireland and Switzerland demonstrated – amongst many other positive effects – an improvement in user satisfaction and social interactions of people with dementia risk, a decrease in the burden on primary caregivers and measurable reduction in primary care visits, as well as better adherence to cognitive stimulation and physical activity plans. In the next phase, the project is expanding to South Africa as the technology creates most value in low-to-middle-income countries.

This project builds on previous datasets from our group that include more than 2,700 patients and have shown 87-94% diagnostic accuracy in predicting Alzheimer’s up to six years in advance. Obtaining information early enables prevention. Partners in this project are ETH Zürich, Trinity College Dublin, University of Barcelona, GMV Innovating Solutions and IDIBAPS.

A summary of some of the project’s achievements so far can be found below:

  • The EIT Health project had a formal interview for the Swiss national TV channel on the value of early screening for dementia prevention together with the 3 leading dementia experts at Switzerland. The interview also demonstrated Altoida, which is now supported by the Swiss Alzheimer’s Association and will play at SRF (National channel) on June 20th at 7pm. The estimated audience is 500k people.
  • Altoida is participating at the winning EU proposal for IMI RADAR-AD with EUR 15m funding together with Takeda, Janssen, Novartis, Eli Lilly, Alzheimer Association EU etc.
  • Sandi Chapman and her team from the Dallas Brain Health Institute realised the potential of the technology, which will support them in becoming the global leader in Brain Health checkup & treatment and put the Project Brain-Health 2027 in the spotlight. They want to be at the forefront of Brain-Health and our technology will be integrated for at least 120.000 patients measured!
  • ADPS received co-financing from the Alzheimer’s Association Switzerland (CHF 60k) for their Swiss pilots.
  • Ioannis Tarnanas from ETH Zürich has been invited to speak at Lausanne V: Transforming Health Systems to Change the Course of Alzheimer’s Disease. The meeting will be held from 9-10 October 2018 at the Beaulieu Lausanne Convention Center in Lausanne, Switzerland. Swiss Federal Office of Public Health saw him presenting the Altoida technology in a recent talk and invited him afterwards to their event.

First results from the ADPS pilot roll-out at USA, Spain, Greece, Italy, Ireland and Switzerland are: improvement at the provision of giving appropriate information to patients, improvement in user satisfaction, the physical activity space and social interactions of people with dementia risk, decrease in the caregiver burden and primary care visits, as well as better adherence to cognitive stimulation and physical activity. The improvement was seven times more than the baseline at the high income participants and more than ten times more at the low literacy (low-middle income) participants compared to the baseline. The next roll-out will be in South Africa, Cape Town, since the technology creates much more impact at Low and Middle Income Countries (LAMIC). An investigation of potential synergies with the STRIDE project has been initiated. The STRIDE program will build research capability in using economics, epidemiology and policy analysis to help LAMICs respond to the needs of the growing numbers of people with dementia in an ethical and sustainable way.

For more information, please contact:

Ioannis Tarnanas, ETH Zürich

Back to top
Image of